Functional and Aesthetic Periorbital, Ocular Adnexal and Ocular Surface Changes Linked to GLP-1 Receptor Agonists
Journal of Clinical Medicine · 12.12.2025 · 14 (24) · 8792
DOI: 10.3390/jcm14248792 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 12.12.2025. Verfasst von Dimitrios Kapantais und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Northern Care Alliance NHS Foundation Trust, Rochdale OL12 0NB, UK. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists have revolutionised obesity and type 2 diabetes management through effective weight loss and metabolic regulation. However, their increasing use has led to reports of adverse aesthetic and functional effects, particularly affecting facial and ocular tissues.
Methods
A comprehensive literature review was conducted in October 2025 across PubMed, Embase, and Medline using the terms “GLP-1 receptor agonist,” “Ozempic face,” “facial lipoatrophy,” “ocular surface disease,” “orbital fat,” and related combinations. Studies reporting facial, periorbital, orbital, or ocular surface changes associated with GLP-1 or GLP-1/GIP receptor agonists were included. Reference lists were screened to identify additional sources.
Results
Evidence suggests that GLP-1 and dual GLP-1/GIP receptor agonists may contribute to rapid facial volume loss, dermal fat atrophy, and periocular hollowing—collectively termed “Ozempic face.” The mechanism is multifactorial, involving both weight-loss-related fat depletion and potential modulation of adipocyte differentiation. Ocular surface improvements have been observed in some studies. Radiologic data demonstrate preferential superficial midface fat loss, informing potential aesthetic correction strategies.
Conclusions
GLP-1-based therapies, while clinically effective, can result in perceptible adnexal and periocular changes with aesthetic and functional implications. Awareness of these effects is crucial for multidisciplinary management. Future prospective studies are warranted to clarify mechanisms and guide individualised reconstructive and rejuvenative interventions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology, Northern Care Alliance NHS Foundation Trust, Rochdale OL12 0NB, UK.
- Faculty of Medical and Human Sciences, The University of Manchester, Manchester M13 9PT, UK.
ORCID-Profile: Dimitrios Kapantais, Panagiotis Tsoutsanis
Zitieren
APA
Kapantais, D., & Tsoutsanis, P. (2025). Functional and Aesthetic Periorbital, Ocular Adnexal and Ocular Surface Changes Linked to GLP-1 Receptor Agonists. Journal of Clinical Medicine, 14(24), 8792. https://doi.org/10.3390/jcm14248792
Vancouver
Kapantais D, Tsoutsanis P. Functional and Aesthetic Periorbital, Ocular Adnexal and Ocular Surface Changes Linked to GLP-1 Receptor Agonists. Journal of Clinical Medicine. 2025;14(24):8792. doi:10.3390/jcm14248792
BibTeX
@article{Kapantais2025,
author = {Kapantais, Dimitrios and Tsoutsanis, Panagiotis},
title = {Functional and Aesthetic Periorbital, Ocular Adnexal and Ocular Surface Changes Linked to GLP-1 Receptor Agonists},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {24},
pages = {8792},
doi = {10.3390/jcm14248792}
}
EUVIMED